Welcome to EpilepsyU.com a social network dedicated to the epilepsy community


UCB Announces BRIVIACT® (Brivaracetam) now Approved by FDA to Treat Partial-onset (Focal) Seizures in Pediatric Epilepsy Patients

BRIVIACT® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures   – Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic dose from day one   – Pediatric epilepsy is the most common, serious neurological disorder among children and young adults, thought to affect nearly 470,000 children in the U.S[1],[2]   – Indication comes less than 2 years after the launch of BRIVIACT in the U.S., building on existing adult monotherapy and adjunctive therapy indications, and broadening clinical application for UCB’s newest anti-epilepsy drug   UCB announced today that the U.S. Food and Drug Administration (FDA...

Lost Password